Literature DB >> 26489081

The COMTp.Val158Met Polymorphism and Cognitive Performance in Adult Development, Healthy Aging and Mild Cognitive Impairment.

Christina Degen1, Johannes Zschocke, Pablo Toro, Christine Sattler, Hans-Werner Wahl, Peter Schönknecht, Johannes Schröder.   

Abstract

BACKGROUND: The impact of genetic polymorphisms on cognition is assumed to increase with age as losses of brain resources have to be compensated for. We investigate the relation of catechol-O-methyltransferase (COMT)p.Val158Met polymorphism and cognitive capacity in the course of adult development, healthy aging and the development of mild cognitive impairment (MCI) in two birth cohorts of subjects born between 1930 and 1932 or between 1950 and 1952.
METHODS: Thorough neuropsychological assessment was conducted in a total of 587 participants across three examination waves between 1993 and 2008. The COMT genotype was determined as a restriction fragment length polymorphism after PCR amplification and digestion with NlaIII.
RESULTS: Significant effects of the COMTp.Val158Met polymorphism were identified for attention and cognitive flexibility in the younger but not the older cohort.
CONCLUSION: These results confirm the importance of the COMTp.Val158Met genotype on tasks assessing attention and cognitive flexibility in midlife but not in healthy aging and the development of MCI. Our findings suggest that the influence of COMT changes as a function of age, decreasing from midlife to aging.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26489081     DOI: 10.1159/000439585

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  1 in total

1.  Genetic association study of dyslexia and ADHD candidate genes in a Spanish cohort: Implications of comorbid samples.

Authors:  Mirian Sánchez-Morán; Juan Andrés Hernández; Jon Andoni Duñabeitia; Adelina Estévez; Laura Bárcena; Aintzane González-Lahera; María Teresa Bajo; Luis J Fuentes; Ana M Aransay; Manuel Carreiras
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.